SuMMARY Patent ductus arteriosus (PDA) was diagnosed in 27 (21 %) of 129 infants weighing < 1500 g at birth presenting over I years. The incidence of PDA in infants with pulmonary disease, particularly hyaline membrane disease, was higher than that in infants without such disease (31% compared with 16% Results suggest that (1) extremely preterm infants are less likely to respond to indomethacin, (2) success is more likely in the first 10 days of life, (3) a total dose greater than 0.6 mg/kg will not increase the success rate, (4) selective morbidity from indomethacin is unlikely ifthe contraindications of bleeding tendency, hyperbilirubinaemia, and renal dysfunction are followed, although urinary output must be monitored carefully, (5) indomethacin is a useful alternative to surgical ligation although long-term prognosis from clinical trials has yet to be established.
Improvement in neonatal intensive care has resulted in greater survival of preterm infants, and increased diagnosis of disorders associated with prematuritysuch as patent ductus arteriosus (PDA). Management of PDA has become one of the major problems in neonatal intensive care.1 For most preterm infants with PDA, conservative medical management is satisfactory.2-3 If cardiac or respiratory failure is progressive and life-threatening despite aggressive medical management, immediate ductal closure is essential for infant survival." Small preterm infants < 1500 g with or without hyaline membrane disease (HMD) often have a prolonged course of ductus shunting and characteristically require weeks of mechanical ventilation. A recent study showed that early ductal closure led to earlier weaning from mechanical ventilation, decreased need for antifailure treatment, and earlier establishment of optimal nutrition via the enteric route.7 Friedman et Indometlhacin therapy. The 16 infants with sPDA who had persistent CCF or were ventilator-dependent despite antifailure treatment were treated with indomethacin. Their median birthweight was 840 g (range 620-1340) and median gestational age 26 weeks (range 24-28). 12 of the infants weighed < 1000 g. The first dose of indomethacin was administered between 8 and 22 days (median 10). Only 6 of 16 infants received the first dose before 10 days of age.
After the administration of indomethacin the time taken for clinical and echocardiographic evidence of ductal closure varied as did the number of doses needed to achieve this. Ductal closure with complete disappearance of both the PDA murmur and signs of CCF with return of echocardiogram to normal occurred in 9 (56%) infants. This was achieved within 24 hours of a single dose in 4 infants, and after a course of two doses in 5 infants. The murmur became softer and there was pronounced clinical and echocardiographic improvement in a further 3 (19%) infants. Four (25%) infants failed to respond to indomethacin despite two courses of treatment in 3 infants and three courses of treatment in the other. 
